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a b s t r a c t
Aim: Valproic acid (VPA) is used in epilepsy treatment and as a stabilizer in bipolar affective
disorder for over 40 years. Although, the pharmacokinetic properties of valproic acid are well
known, it is often forgotten that the formulation of the drug signiﬁcantly inﬂuences its
gastrointestinal absorption.
Case: We are describing the case of 30 year-old female patient, diagnosed at the age of 13
with juvenile myoclonic epilepsy. Complete ineffectiveness of the treatment was caused by
malabsorption of sodium valproate and valproic acid in the patient. The change of the drug
formulation resulted in a several times higher bioavailability of the drug and a partial
improvement of the patient's clinical condition.
Commentary: Low concentration of valproic acid after administration the slow-released
tablets are usually observed. However, a low bioavailability beside the bad compliance
should be considered when the minimal level is extremely low during therapy. It is known
that form of the drug, beside presence of food and its components, as well as gastrointestinal
tract condition or interactions with other drugs can inﬂuence the drug level. Modiﬁcation of
the formulation of the drug may lead to improvement of absorption and increase its
effectiveness.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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Valproic acid has been used in medicine since 1970s. At the
beginning it was administered for the treatment of partial-
onset and generalized seizures, at present it is used to stabilize
mood, in paroxysmal hemicrania prophylaxis, and in the
treatment of mental illnesses.* Corresponding author at: Instytut Psychiatrii i Neurologii/Institute of
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0028-3843/© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish NValproic acid can be applied in a wide range of indications
due to its multi-directional effects. It inﬂuences the level of
g-aminobutyric acid (GABA) in the brain and blocks the
voltage-gated ion channels. Experiments conducted in vitro,
as well as in vivo, revealed that valproic acid inhibits GABA
transaminase (ABA7) and succinic semialdehyde dehydroge-
nase (ALDH55A1), enzymes involved in GABA metabolism.
The above- mentioned mechanism results in an increase of Psychiatry and Neurology, Sobieskiego 9, Warsaw, Poland.
eurological Society.
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impaired in epileptic seizures. [1] The anticonvulsant effect
is also due to a decrease of neuronal discharges by blockade of
the voltage-gated sodium, potassium and calcium channels,
as well as inhibition of depolarization initiated by the NMDA
receptor, and modiﬁcation of cellular signaling pathways,
such as kynurenine pathway [1–5]. Its multi-directional
mechanisms of action are believed to be responsible for a
very high effectiveness in different types of seizures.
In clinical practice, valproic acid (sodium salt) is adminis-
tered parenterally, orally and rectally. The most common oral
formulations include syrup, suspension, immediate-release or
prolonged-release tablets and enteric-coated tablets. The rate
of absorption of oral preparations depends on the form of the
drug, and it is the highest, when administered in solution [6].
Bioavailability of the drug is believed to be comparable for
different oral formulations.
The drug highly bounds to blood proteins, mainly albumins
(87–95%) with low plasma clearance (6–20 ml/h/kg). Bounding
decreases with increasing drug concentration in the blood. The
therapeutic plasma concentration of valproic acid in long-
term therapy varies between 40 and 100 mg/ml (280–700 mmol/
L). Less than 3% of the drug is excreted in an unchanged form
with urine. The remaining part undergoes biotransformation
in the liver. Valproic acid belongs to fatty acids and,
consequently, is metabolized via endogenous pathway in
mitochondria: through mitochondrial b-oxidation, microsom-
al v and (v-1)-hydroxylation, glucuronidation and other
conjugation reactions. It is excreted mainly with urine, trace
amounts can be also present in the bile, feces and breath. The
main metabolite excreted with urine is valproate glucuronide
[7–9].
In everyday clinical practice, absorption is rarely regarded a
signiﬁcant pharmacological parameter. In this paper, we
would like to highlight essential differences between the
concentration and bioavailability of valproic acid in different
formulations.
2. Case study
A 30 year-old female patient with juvenile myoclonic epilepsy,
diagnosed at the age of 13, was followed up in the hospital out-
patient clinic from the age of 22. The patients suffered from
generalized tonic–clonic, myoclonic and absence seizures with
different frequency since the onset of the disease. Myoclonus
occurred most frequently (a few times every day), typically in
the morning, in upper extremities, but sometimes was
extremely severe, making the patient fall. Generalized
tonic–clonic seizures were less frequent, about 1 per month,
absence seizures about 2 per week. The patient graduated from
secondary school and did not continue education because of
frequent seizures. Cognitive functions did not deteriorate in
the course of the disease. Since her adolescence the patient
was affected by obesity, arterial hypertension and bronchial
asthma. From the beginning of the disease the patient was
treated with high doses of valproic acid (prolonged-release
drugs), not achieving its full effect. Additionally, the patient
received lamotrigine and levetiracetam for about 5 years. All
drugs were used at maximum acceptable doses. There were noseizure free periods in the course of the disease. In 2014 the
patient was admitted to our hospital for observation due to
increased number of seizures. EEG revealed numerous
generalized paroxysmal discharges in the form of spike-
polyspike-slow wave synchronized complexes (Fig. 1). The
valproic acid level during hospitalization in fasting state was
6 mg/ml. A daily dose of valproic acid with sodium valproate in
the form of prolonged-release drug was 2000 mg. As the
patient denied non-adherence to therapy, numerous evalua-
tions of valproic acid level were carried out, after administra-
tion of the recommended dose of the drug. Valproic acid level
was determined before drug intake, as well as 2 and 6 h after
oral administration of sodium valproate with valproic acid in
the form of prolonged-release tablets (1000 mg). The results
indicated malabsorption of the drug (valproic acid level before
administration – 4.92 mg/ml; 2 h after the morning dose –
8.10 mg/ml; 6 h after the morning dose – 18.49 mg/ml). Since the
patient was discharged due to family reasons, the formulation
of the drug was changed to enteric-coated fast-releasing
tablets. Two weeks later the patient was admitted to hospital
again. The drug level in fasting state was at 33.92 mg/ml
(2000 mg/day). The concentration of valproic acid was deter-
mined in the fasting state, as well as 2 h and 6 h after intake of
1000 mg sodium valproate in form of syrup, enteric-coated
tablets, and after intravenous injection. The concentration of
valproic acid 2 and 6 h after administration was 62 mg/ml and
47 mg/ml, respectively, for syrup, 103.81 mg/ml and 94.72 mg/ml
for enteric-coated tablets, and 45.5 mg/ml and at 52 mg/ml for
intravenous administration. The trial revealed normal absorp-
tion of syrup and enteric-coated tablets, therefore enteric-
coated tablets therapy was maintained. The daily dose was
increased to 3000 mg/day. Decreased number of seizures was
achieved during next 4 weeks, as well as improvement of EEG
recording (no abnormalities). At present, generalized tonic–
clonic seizures occur about once a year, the frequency of
myoclonus and absence seizures has also decreased. Valpro-
ates level in fasting state after a few weeks was 58.78 mg/ml.
3. Discussion
Gastrointestinal absorption and bioavailability of drugs,
including valproic acid, depend on the type of preparation.
In our patient malabsorption of sodium valproate with
valproic acid in prolonged-release tablets occurred, with
normal drug concentration after its administration in the
form of syrup and enteric-coated tablets.
Gastrointestinal absorption is inﬂuenced by drug formula-
tion. There are many publications comparing absorption
depending on the formulation. Chun et al. indicated that
absorption rate of valproic acid in syrup is higher than in
capsules. The absorption rate was higher in fasting state and
directly before a meal than after a meal. Bano et al. compared
the pharmacokinetics of valproic acid in healthy volunteers
after administration in capsules, tablets and syrup. Following
the administration, maximum concentration and the time to
peak maximum concentration were the highest for syrup, and
the lowest for capsules. Bioavailability of the drug in capsules
was also lowest. In our patient the drug concentrations were
signiﬁcantly higher when administered in enteric-coated
Fig. 1 – EEG recording showed normal background and numerous generalized discharges of spike-slow wave complexes
activated by hyperventilation.
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[10,11].
Dutta and Reed evaluated 5 preparations with valproic acid/
divalproex sodium [12]. Following administration in fasting
state, in healthy volunteers blood Cmax was the highest for
valproic acid syrup, and the lowest for divalproex sodium
prolonged-release tablets. Royer-Morrot et al. investigated the
inﬂuence of food on pharmacokinetics of sodium valproate
with valproic acid prolonged release tablets. Although Cmax
and Tmax varied depending on whether the drug was
administered in fasting state or after a meal, the total amount
of the drug did not differ in the 12 h following administration [13].
There is also a report demonstrating low concentrations of
valproic acid (27 mg/L) in a patient with bipolar disorder,
receiving 1200 mg of valproic acid amide, who had the surgery
to remove a part of the small intestine. Valproic acid amide, is
a pro-drug, which is transformed to active component –
valproic acid in the small intestine. After changing the amide
to valproic acid, the drug concentration in serum increased,
whereas the symptoms of depression signiﬁcantly improved
within 3 days [14]. In the case of our patient, the reasons for
decreased absorption of the drug in prolonged-release
preparation are difﬁcult to explain. Many factors can modify
the intensity and level of gastrointestinal absorption of thedrug, such as meal components and rate of peristalsis. Data
contained in numerous publications indicate that valproic acid
can inhibit the activity of many microsomal enzymes in the
liver, including CYP2C9. Possible stimulating effect of valproic
acid has been recently stressed. In vitro testing revealed that it
can induce CYP3A4 isoenzyme and P-glycoprotein gene
expression. [15] Studies in healthy volunteers revealed that
valproic acid can induce its own metabolism. [16] Low drug
concentration at standard doses was observed in these cases.
In some rare cases high doses are needed (from 4000 to
10,000 mg/day) to reach therapeutic concentrations [17].
In conclusion, the most probable explanation in the
discussed case is impaired release of valproic acid from
prolonged-release tablets connected with speciﬁc conditions
in the gastrointestinal tract (pH, rate of peristalsis). Adminis-
tration of prolonged-release preparations is always connected
with low concentration of valproic acid in the blood, however
low concentration in the fasting state and abnormal clinical
effect of therapy for several months indicate low bioavailabili-
ty of the drug. In patients with no clinical effect after
administration of standard doses of the drug monitoring of
its blood concentration is mandatory, with change of the
formulation, which can lead to improved drug absorption and
increased effectiveness.
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